HOUSTON, Aug. 6, 2019 /PRNewswire/ -- Marker
Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage
immuno-oncology company specializing in the development of
next-generation T cell-based immunotherapies for the treatment of
hematological malignancies and solid tumor indications, today
announced the appointment of Steve
Elms to its Board of Directors, effective August 6.
"We are pleased to welcome Steve to our Board of Directors,"
said Peter L. Hoang, President &
CEO of Marker. "Steve has built an impressive career, holding
numerous leadership positions in the healthcare sector and we look
forward to his many contributions as we continue to advance our
pipeline of next-generation T cell-based immunotherapies."
Throughout his career, Mr. Elms has held numerous leadership
roles in the healthcare sector. Mr. Elms currently serves as
Managing Partner at Aisling Capital, a leading life sciences
investment firm. Prior to joining Aisling, he was a Principal in
the Life Sciences Investment Banking Group of Chase H&Q
(formerly Hambrecht & Quist), where he was involved in over 60
financing and M&A transactions, helping clients raise in excess
of $3.3 billion in capital.
Prior to H&Q, Mr. Elms traded mortgage-backed securities at
Donaldson, Lufkin & Jenrette. His previous healthcare sector
experience includes over two years as a pharmaceutical sales
representative for Marion Laboratories and two years as a
consultant for The Wilkerson Group. Mr. Elms currently serves as a
director of ADMA Biologics, Ajax Health II and Zosano Pharma and
was previously Chairman of the Board of LOXO Oncology. He also
serves on the INVO Board at Northwestern
University.
Mr. Elms received his M.B.A. from the Kellogg Graduate School of
Management at Northwestern University
and his B.A. in Human Biology from Stanford
University.
About Marker Therapeutics, Inc.
Marker Therapeutics,
Inc. is a clinical-stage immuno-oncology company specializing in
the development of next-generation T cell-based immunotherapies for
the treatment of hematological malignancies and solid tumor
indications. Marker's cell therapy technology is based on the
selective expansion of non-engineered, tumor-specific T cells that
recognize tumor associated antigens (i.e. tumor targets) and kill
tumor cells expressing those targets. This population of T cells is
designed to attack multiple tumor targets following infusion into
patients and to activate the patient's immune system to produce
broad spectrum anti-tumor activity. Because Marker does not
genetically engineer its T cells therapies, we believe that our
product candidates will be easier and less expensive to
manufacture, with reduced toxicities, compared to current
engineered CAR-T and TCR-based approaches, and may provide patients
with meaningful clinical benefit. As a result, Marker believes its
portfolio of T cell therapies has a compelling product profile, as
compared to current gene-modified CAR-T and TCR-based
therapies.
Marker is also advancing a number of innovative peptide- and
gene-based immuno-therapeutics for the treatment of metastatic
solid tumors, including the Folate Receptor Alpha program (TPIV200)
for breast and ovarian cancers and the HER2/neu program
(TPIV100/110) for breast cancer, currently in Phase 2 clinical
trials.
To receive future press releases via email, please
visit: https://markertherapeutics.com/email-alerts/
Forward-Looking Statement Disclaimer
This release contains forward-looking statements for purposes of
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Statements in this news release concerning the
Company's expectations, plans, business outlook or future
performance, and any other statements concerning assumptions made
or expectations as to any future events, conditions, performance or
other matters, are "forward-looking statements." Forward-looking
statements include statements regarding our intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things: our research and development activities
relating to our non-engineered multi-tumor antigen specific T cell
therapies; our TPIV200 and TPIV100/110 programs; the effectiveness
of these programs or the possible range of application and
potential curative effects and safety in the treatment of diseases;
and, the timing and success of our clinical trials, as well as
clinical trials conducted by our collaborators. Forward-looking
statements are by their nature subject to risks, uncertainties and
other factors which could cause actual results to differ materially
from those stated in such statements. Such risks, uncertainties and
factors include, but are not limited to the risks set forth in the
Company's most recent Form 10-K, 10-Q and other SEC filings which
are available through EDGAR at www.sec.gov. The Company assumes no
obligation to update our forward-looking statements whether as a
result of new information, future events or otherwise, after the
date of this press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/marker-therapeutics-appoints-steve-elms-to-its-board-of-directors-300897461.html
SOURCE Marker Therapeutics, Inc.